San Francisco Bay Area biotech stories.
Tuesday, September 4, 2012
StemCells finds early data from spinal cord injury trial promising
StemCells CEO Martin McGlynn.
Early data from an early-stage trial in spinal cord patients by StemCells Inc. indicated that two of three patients with the worst kind of spinal cord injuries started recovering feeling
. The Newark company (NASDAQ: STEM), which is developing human neural stem cells, is the first to report data from a stem cells trial in spinal cord injuries, a spokeswoman said.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)